<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00504933</url>
  </required_header>
  <id_info>
    <org_study_id>BILA 1704/RAE</org_study_id>
    <secondary_id>2004-004586-14</secondary_id>
    <nct_id>NCT00504933</nct_id>
  </id_info>
  <brief_title>Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis</brief_title>
  <official_title>Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Cetirizine 10 mg for the Treatment of Seasonal Allergic Rhinitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faes Farma, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Faes Farma, S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the efficacy and tolerability of Bilastine 20 mg,
      compared to Cetirizine and placebo for the treatment of seasonal allergic rhinitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this pivotal, multicentre, international, randomized, double-blind, placebo and
      active-comparator controlled, parallel study, 683 patients with SAR will be enrolled.
      Patients will be required to be 12-70 years old, have SAR for ≥2 years, a positive skin test,
      total nasal and non-nasal score (TSS) ≥36 (out of 72) during run-in, and a composite
      instantaneous nasal symptom score ≥6 (out of 12) the morning before randomization. The
      primary efficacy endpoint will be the AUC of reflective TSS from baseline to Day 14.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve of total symptoms score (TSS) from basal visit to D14 visit, according to the patient's assessment on reflective symptoms.</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC of TSS from baseline to D14 according to the patient's assessments on instantaneous symptoms.</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at day 7 and day 14 for the following: Patient-rated (reflective and instantaneous) and Investigator-rated (instantaneous; assessed during study visit) TSS, NSS, NNSS and change for each individual symptom.</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall assessment of discomfort caused by SAR using a visual analogue scale (VAS) on day 7 and day 14 vs. day 0.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-rated Clinical Global Impression (CGI) - assessment of the therapeutic effect and AEs performed at day 14</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responders Rate: responders will be classified based on their TSS decrease from baseline: no responders (&lt;25%), &gt;25%&lt;50%, &gt;50%&lt;75%, &gt;75% and will be described by treatment group with their percentage</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">683</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bilastine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cetirizine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bilastine</intervention_name>
    <description>20 mg (encapsulated) tablets QD/14days</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetirizine</intervention_name>
    <description>10 mg (encapsulated) tablets. QD/14 days</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Zyrtec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>(encapsulated) Tablets QD/14 days</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of either sex between 12 and 70 years of age.

          -  Patients with documented clinical history of SAR, for at least 2 years prior to the
             study inclusion.

          -  Positive skin prick test for at least one of the seasonal allergen specific of the
             geographical area.

          -  A previous positive Prick test, or a positive IgE Test (RAST) may also be accepted for
             inclusion, if performed within 12 months prior to the inclusion.

        Exclusion Criteria:

          -  Patients who have non-allergic rhinitis (vasomotor, infectious, drug-induced, etc.).

          -  Negative skin prick test (as defined in point 6.1.1.).

          -  Patients with nasal polyps or a significant deviation of the nasal septum as judged by
             the investigator as well as nasal intervention in the previous 6 months. Any other
             nasal illness that can interfere with the aim of the study.

          -  Patients who have acute or chronic sinusitis as judged by the investigator.

          -  Patients who have received anti-allergy immunotherapy in the previous two years or are
             still receiving this kind of therapy.

          -  Patients who are taking or have taken specified medications prior to randomisation in
             the study and have not complied with the specified washout period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piotr Kuna, Prof. Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barlicki University Hospital, Medical University of Lodz (Poland)</affiliation>
  </overall_official>
  <reference>
    <citation>Bousquet J, Ansótegui I, Canonica GW, Zuberbier T, Baena-Cagnani CE, Bachert C, Cruz AA, González SN, Kuna P, Morais-Almeida M, Mullol J, Ryan DP, Sánchez-Borges M, Valiente R, Church MK. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Curr Med Res Opin. 2012 Jan;28(1):131-9. doi: 10.1185/03007995.2011.648263. Epub 2011 Dec 22. Review.</citation>
    <PMID>22149770</PMID>
  </reference>
  <reference>
    <citation>Church MK. Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Saf. 2011 Sep;10(5):779-93. doi: 10.1517/14740338.2011.604029. Epub 2011 Aug 11. Review. Erratum in: Expert Opin Drug Saf. 2012 Jan;11(1):175.</citation>
    <PMID>21831011</PMID>
  </reference>
  <reference>
    <citation>Jáuregui I, García-Lirio E, Soriano AM, Gamboa PM, Antépara I. An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria. Expert Rev Clin Immunol. 2012 Jan;8(1):33-41. doi: 10.1586/eci.11.87. Review.</citation>
    <PMID>22149338</PMID>
  </reference>
  <results_reference>
    <citation>Kuna P, Bachert C, Nowacki Z, van Cauwenberge P, Agache I, Fouquert L, Roger A, Sologuren A, Valiente R; Bilastine International Working Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy. 2009 Sep;39(9):1338-47. doi: 10.1111/j.1365-2222.2009.03257.x. Epub 2009 May 4.</citation>
    <PMID>19438584</PMID>
  </results_reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2007</study_first_submitted>
  <study_first_submitted_qc>July 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2007</study_first_posted>
  <last_update_submitted>April 4, 2012</last_update_submitted>
  <last_update_submitted_qc>April 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rhinitis</keyword>
  <keyword>Allergic</keyword>
  <keyword>Seasonal</keyword>
  <keyword>Hay Fever</keyword>
  <keyword>Pollen Allergy</keyword>
  <keyword>Pollinosis</keyword>
  <keyword>Rhinoconjunctivitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetirizine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

